Daiichi Sankyo Co.

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Daiichi Sankyo Co. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Daiichi Sankyo Co.: 8 sponsored US clinical trials, none currently recruiting.

Daiichi Sankyo Co. sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Malignant, with 1 trials.

Upper-quartile sponsor footprint

Daiichi Sankyo Co. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

NCT03401385
ACTIVE NOT RECRUITING Phase 1

DS-3201b in Participants With Lymphomas

NCT02732275
TERMINATED Phase 1

A Study of DS-1471a In Subjects With Advanced Solid Tumors

NCT06074705
COMPLETED Early Phase 1

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

NCT04459585
COMPLETED Phase 1

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

NCT04459598
COMPLETED Phase 2

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

NCT03384940
COMPLETED Phase 1

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

NCT02980341
COMPLETED Phase 1

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

NCT02564900

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1

Therapeutic Areas

Lymphoma, Malignant 1
Non-Hodgkin Lymphoma 1
Hormone Receptor-Positive Breast Cancer 1
Triple Negative Breast Cancer 1
Advanced Solid Tumors 1
Non-Small Cell Lung Cancer 1

How the Daiichi Sankyo Co. early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Lymphoma, Malignant (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Daiichi Sankyo Co.: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Daiichi Sankyo Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Daiichi Sankyo Co.AB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Daiichi Sankyo Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Daiichi Sankyo Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Daiichi Sankyo Co. page

8 registered trials is a research-attention snapshot, not an endorsement of Daiichi Sankyo Co. or any single study.

  • None of Daiichi Sankyo Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Lymphoma, Malignant is the condition Daiichi Sankyo Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Malignant trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Daiichi Sankyo Co. pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.